Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B
Top Cited Papers
- 5 August 2012
- journal article
- research article
- Published by Springer Science and Business Media LLC in Nature Medicine
- Vol. 18 (9), 1359-1368
- https://doi.org/10.1038/nm.2890
Abstract
Responses to anticancer therapy are hampered by several factors, and Peter S. Nelson and colleagues here identify a protective effect of the tumor microenvironment. After cytotoxic chemotherapy, inflammatory NF-κB signaling activates the secretion of WNT16B, which acts on epithelial cells, promoting their survival and fostering tumor growth in vivo. This pathway is also active in human tumors treated with chemotherapy and illustrates the potential caveats of cyclical therapy and the need to overcome environmental protection to successfully eliminate tumors. Acquired resistance to anticancer treatments is a substantial barrier to reducing the morbidity and mortality that is attributable to malignant tumors. Components of tissue microenvironments are recognized to profoundly influence cellular phenotypes, including susceptibilities to toxic insults. Using a genome-wide analysis of transcriptional responses to genotoxic stress induced by cancer therapeutics, we identified a spectrum of secreted proteins derived from the tumor microenvironment that includes the Wnt family member wingless-type MMTV integration site family member 16B (WNT16B). We determined that WNT16B expression is regulated by nuclear factor of κ light polypeptide gene enhancer in B cells 1 (NF-κB) after DNA damage and subsequently signals in a paracrine manner to activate the canonical Wnt program in tumor cells. The expression of WNT16B in the prostate tumor microenvironment attenuated the effects of cytotoxic chemotherapy in vivo, promoting tumor cell survival and disease progression. These results delineate a mechanism by which genotoxic therapies given in a cyclical manner can enhance subsequent treatment resistance through cell nonautonomous effects that are contributed by the tumor microenvironment.Keywords
This publication has 46 references indexed in Scilit:
- Chemotherapy Sensitivity and Resistance Assays: A Systematic ReviewJournal of Clinical Oncology, 2004
- Digital karyotyping identifies thymidylate synthase amplification as a mechanism of resistance to 5-fluorouracil in metastatic colorectal cancer patientsProceedings of the National Academy of Sciences of the United States of America, 2004
- Phase I Study of Weekly Mitoxantrone and Docetaxel before Prostatectomy in Patients with High-Risk Localized Prostate CancerClinical Cancer Research, 2004
- Involvement of Rel/Nuclear Factor-κB Transcription Factors in Keratinocyte SenescenceCancer Research, 2004
- Chemotherapy response and resistanceCurrent Opinion in Genetics & Development, 2002
- Phenotypic Reversion or Death of Cancer Cells by Altering Signaling Pathways in Three-Dimensional ContextsJNCI Journal of the National Cancer Institute, 2002
- Molecular and physiologic mechanisms of drug resistance in cancer: an overview.Cancer and Metastasis Reviews, 2001
- Repopulation of tumour cells between cycles of chemotherapy: a neglected factorThe Lancet Oncology, 2000
- Genetic analysis of chemoresistance in primary murine lymphomasNature Medicine, 2000
- Comparative study of doxorubicin, mitoxantrone, and epirubicin in combination with ICRF-187 (ADR-529) in a chronic cardiotoxicity animal model.1992